Breakthroughs in cancer therapies and supportive care have dramatically improved life expectancy for patients with hematological malignancies (HM). However, living longer means more patients are surviving long enough to encounter severe, acute complications that require intensive care unit (ICU) admission.

Because these emergencies happen globally—not just at major academic research hospitals—all intensivists must understand how to manage them.

Treating critically ill HM patients demands a highly coordinated, multi-professional approach, often requiring smaller community ICUs to stabilize patients before safely transferring them to specialized centers.

A Shift in Prognosis: Improved survival rates mean more HM patients are candidates for intensive care with a genuine potential for full recovery.

The CAUSE Diagnostic Framework: To determine the root of a crisis, clinicians can map complications based on the timeline of the patient’s cancer journey:

C & A (Cancer-related & Associated complications): Typically strike at initial diagnosis or during relapsed/refractory phases.

U, S & E (Infections & Treatment-related complications): Most commonly arise after therapy has already been initiated.

The Diagnostic Puzzle: Intensivists must synthesize the exact chronology of symptoms, the specific type of immunosuppression, and distinct laboratory/radiological patterns to guide their investigations for acute respiratory failure (ARF), sepsis, or acute kidney injury (AKI).

Ventilation Strategy Nuance: Respiratory failure is a major threat, but evidence remains limited as HM patients are historically excluded from large clinical trials.

Current data suggests:

– Intubation should be avoided if possible, but never delayed when truly necessary.
– No single oxygenation strategy (conventional oxygen, high-flow nasal oxygen, or non-invasive ventilation) is superior; treatments must be highly individualized.

Read More